Latest News and Press Releases

Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology A

Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet

Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October

Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate

Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a favorable safety profile to date and the potential to significantly...

Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer

Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference